Table 4.
Posttransplant complications
| Complication | Non-EVR group (n=189) | EVR group (n=114) | P-value |
|---|---|---|---|
| Suspected acute cellular rejection | 25 (13.2) | 15 (13.1) | 0.986 |
| Steroid-resistant rejection | 0 (0.0) | 0 (0.0) | - |
| Biliary complications | 40 (21.2) | 21 (18.4) | 0.564 |
| Hepatic artery stenosis | 0 (0.0) | 0 (0.0) | - |
| Hepatic artery thrombosis | 3 (1.6) | 0 (0.0) | - |
| Portal vein thrombosis | 3 (1.6) | 1 (0.9) | 0.600 |
| Wound infection | 24 (12.7) | 13 (11.4) | 0.739 |
| Dyslipidemia | 39 (20.6) | 39 (34.2) | 0.009 |
| Proteinuria | 36 (19.0) | 37 (32.5) | 0.008 |
| Mouth ulcers | 8 (4.2) | 11 (9.6) | 0.060 |
| Renal failure | 2 (1.0) | 1 (0.9) | 0.877 |
Values are presented as number (%).
EVR, everolimus.